(Q46378368)

21 December 2017

title

Retrospective evaluation of a possible interaction between warfarin and levofloxacin (English)

1 reference

21 December 2017

1 reference

Kenneth L McCall

1

1 reference

21 December 2017

John C Scott

series ordinal

2

1 reference

21 December 2017

H Glenn Anderson

series ordinal

3

1 reference

21 December 2017

language of work or name

English

0 references

publication date

1 January 2005

1 reference

21 December 2017

published in

Pharmacotherapy

1 reference

21 December 2017

volume

25

1 reference

21 December 2017

issue

1

1 reference

21 December 2017

page(s)

67-73

1 reference

21 December 2017

Antimicrobial resistance--why do we have it and what can we do about it?

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Antimicrobial resistance--should we be concerned?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Why is big Pharma getting out of antibacterial drug discovery?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Antibacterials: are the new entries enough to deal with the emerging resistance problems?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Antibiotic resistance in the intensive care unit setting

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Vancomycin resistance in Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Bridges from hospitals to the laboratory: genetic portraits of methicillin-resistant Staphylococcus aureus clones.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Community-acquired methicillin-resistant Staphylococcus aureus skin infection: a retrospective analysis of clinical presentation and treatment of a local outbreak

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Antibiotic resistance from two perspectives: man and microbe

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Antibiotic resistance in Staphylococcus aureus: concerns, causes and cures

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Methicillin-resistant Staphylococcus aureus in hospitals and the community: stealth dynamics and control catastrophes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Bacterial resistance--the clinical challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Staphylococci in colonization and disease: prospective targets for drugs and vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Biologic properties and vaccine potential of the staphylococcal poly-N-acetyl glucosamine surface polysaccharide

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Review: Nomenclature and Biologic Significance of Cytokines Involved in Inflammation and the Host Immune Response

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

The Problems and Challenges of Immunotherapy in Sepsis*

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Mechanisms of antimicrobial resistance: their clinical relevance in the new millennium

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Evaluation of synergism between the aminoglycoside antibiotic streptomycin and the cardiovascular agent amlodipine.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Topical antibacterial treatments for acne vulgaris : comparative review and guide to selection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Intravitreal taurolidine against experimental Staphylococcus epidermidis endophthalmitis in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Molecular design of multifunctional antibacterial agents against methicillin resistant Staphylococcus aureus (MRSA).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Evaluation of a synergistic combination between the non-antibiotic microbicides diclofenac and trifluoperazine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Sensitization of Burkholderia cepacia to antibiotics by cationic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Targeting bacterial virulence: the role of protein synthesis inhibitors in severe infections. Insights from the Society of Infectious Diseases Pharmacists

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Identification of the histidine protein kinase KinB in Pseudomonas aeruginosa and its phosphorylation of the alginate regulator algB

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Inhibitors of two-component signal transduction systems: inhibition of alginate gene activation in Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Suppression of drug-resistant Staphylococcal Infections by the quorum-sensing inhibitor RNAIII-inhibiting peptide.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Virulence factors of the coagulase-negative staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Conformationally-restricted analogues of efflux pump inhibitors that potentiate the activity of levofloxacin in Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Peptidomimetics of efflux pump inhibitors potentiate the activity of levofloxacin in Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

The AcrB multidrug transporter plays a major role in high-level fluoroquinolone resistance in Salmonella enterica serovar typhimurium phage type DT204.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Host-pathogen interactions: basic concepts of microbial commensalism, colonization, infection, and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Bacterial Resistance to Antimicrobial Host Defenses - An Emerging Target for Novel Antiinfective Strategies?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

A practical look at the clinical usefulness of the beta-lactam/beta-lactamase inhibitor combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

The discovery and development of modified penicillin- and cephalosporin-derived beta-lactamase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Modulation of host defenses by cytokines: evolving adjuncts in prevention and treatment of serious infections in immunocompromised hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Cytokine immunotherapy during bacterial pneumonia: from benchtop to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Intravenous immune globulin for the prevention of nosocomial infection in low-birth-weight neonates. The Multicenter Group for the Study of Immune Globulin in Neonates

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Manipulating the Immune System with Immune Globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Clinical usefulness of intravenous human immunoglobulins in invasive group A Streptococcal infections: case report and review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Immunomodulation for the prevention and treatment of lung infections

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Activation of neutrophils and inhibition of the proinflammatory cytokine response by endogenous granulocyte colony-stimulating factor in murine pneumococcal pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Immunomodulators in infectious diseases: panoply of possibilites

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Immunotherapeutics for nosocomial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Adjunctive efficacy of granulocyte colony-stimulating factor on treatment of Pseudomonas aeruginosa pneumonia in neutropenic and non-neutropenic hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Effects of adjunctive treatment with combined cytokines in a neutropenic mouse model of multidrug-resistant Enterococcus faecalis septicemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Intravenous immune globulin prophylaxis of late-onset sepsis in premature neonates

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Severe sepsis and septic shock. Definitions, epidemiology, and clinical manifestations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

The prevention of antibiotic resistance during treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Clinical failures of linezolid and implications for the clinical microbiology laboratory

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Variety of beta-lactamases produced by amoxicillin-clavulanate-resistant Escherichia coli isolated in the northeastern United States

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Antibiotic resistance rates and phenotypes among isolates of Enterobacteriaceae in French extra-hospital practice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Evolution and epidemiology of extended-spectrum beta-lactamases (ESBLs) and ESBL-producing microorganisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Evolution and clinical importance of extended-spectrum beta-lactamases.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Emerging carbapenemases in Gram-negative aerobes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Determinants of binding affinity and specificity for the interaction of TEM-1 and SME-1 beta-lactamase with beta-lactamase inhibitory protein

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

SME-type carbapenem-hydrolyzing class A beta-lactamases from geographically diverse Serratia marcescens strains

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Efflux-mediated multiresistance in Gram-negative bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

A multidrug efflux pump inhibitor reduces fluoroquinolone resistance in Pseudomonas aeruginosa isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

The AcrAB-TolC pump is involved in macrolide resistance but not in telithromycin efflux in Enterobacter aerogenes and Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

The relationship between physicochemical properties, in vitro activity and pharmacokinetic profiles of analogues of diamine-containing efflux pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Recent progress in the development of vaccines for infants and children

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Epiglottitis in the Hemophilus influenzae type B vaccine era: changing trends

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Interactions among strategies associated with bacterial infection: pathogenicity, epidemicity, and antibiotic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Can virulence factors be viable antibacterial targets?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Bacterial Biofilms: An Emerging Link to Disease Pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Bacterial biofilms of importance to medicine and bioterrorism: proteomic techniques to identify novel vaccine components and drug targets

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

The damage-response framework of microbial pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Listening in on bacteria: acyl-homoserine lactone signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Molecular mechanisms of bacterial quorum sensing as a new drug target

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

The Pseudomonas aeruginosa RpoS regulon and its relationship to quorum sensing.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Synthetic furanones inhibit quorum-sensing and enhance bacterial clearance in Pseudomonas aeruginosa lung infection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Developing inhibitors to selectively target two-component and phosphorelay signal transduction systems of pathogenic microorganisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Virulence gene regulation by peptides in staphylococci and other Gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Lysostaphin Disrupts Staphylococcus aureus and Staphylococcus epidermidis Biofilms on Artificial Surfaces

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

21 January 2018

Bacteriophage Therapy

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Low-dose dexamethasone as adjunctive therapy for disseminated Mycobacterium avium complex infections in AIDS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Mycobacteria and other environmental organisms as immunomodulators for immunoregulatory disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Identification of small molecule inhibitors of anthrax lethal factor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

Prevalence and characterization of macrolide resistance in clinical isolates of Streptococcus pneumoniae and Streptococcus pyogenes from North America

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.2.1.67

21 January 2018

Identifiers

DOI

10.2217/14750708.2.1.67

1 reference

21 December 2017

1 reference

21 December 2017